Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - Investing News Network

Investing News Network

Relmada loses another $21.8M, makes progress with clinical trials - Green Market Report

Green Market Report

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Earnings call: Relmada Therapeutics reports Q1 2024 financials By Investing.com - Investing.com

Investing.com

Down 22.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Relmada Therapeutics, Inc. (RLMD) - Yahoo Singapore News

Yahoo Singapore News

Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic Progress Amid Financial ... - GuruFocus.com

GuruFocus.com

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - PR Newswire

PR Newswire

Relmada Therapeutics (RLMD) Set to Announce Earnings on Wednesday - MarketBeat

MarketBeat

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May ... - BioSpace

BioSpace

Bullish Relmada Therapeutics Insiders Loaded Up On US$695.2k Of Stock - Simply Wall St

Simply Wall St

Major Depressive Disorder Market Report 2032: Epidemiology, Pipeline Therapies, Latest Drug Approvals | DelveInsight - WICZ

WICZ

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop (NASDAQ:RLMD) - Seeking Alpha

Seeking Alpha

Relmada Therapeutics trims losses, slashes research costs - Green Market Report

Green Market Report

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results - PR Newswire

PR Newswire

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation - Simply Wall St

Simply Wall St

Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying

Benzinga

Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying - Processa Pharma (NASDAQ:PCSA), PaySig - Benzinga

Benzinga

RLMD Stock Quote Price and Forecast - CNN

CNN

Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Relmada Therapeutics Provides Corporate Update - PR Newswire

PR Newswire

5 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey

Insider Monkey

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results - PR Newswire

PR Newswire

Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies ... - GlobeNewswire

GlobeNewswire

Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 - PR Newswire

PR Newswire

Promise for Relmada Therapeutics's antidepressant REL-1017, but more data required - Clinical Trials Arena

Clinical Trials Arena

Relmada reports positive results from trial of MDD therapy - Clinical Trials Arena

Clinical Trials Arena

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in ... - PR Newswire

PR Newswire

Relmada doses first patient in MDD therapy trial - Clinical Trials Arena

Clinical Trials Arena

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive ... - PR Newswire

PR Newswire

7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick - InvestorPlace

InvestorPlace

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors - PR Newswire

PR Newswire

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer - PR Newswire

PR Newswire

Relmada reports data from trial of REL-1017 for major depressive disorder - Clinical Trials Arena

Clinical Trials Arena

Steve Cohen Buys 7.3% Of Relmada After Stock Fell 80% Last Week - ValueWalk

ValueWalk

'Paradoxical' placebo response spells Phase 3 failure for Relmada depression drug - MedCity News

MedCity News

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of ... - PR Newswire

PR Newswire

Can Relmada's fast-acting depression pill compete in a crowded market? - Pharmaceutical Technology

Pharmaceutical Technology

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and ... - PR Newswire

PR Newswire

What Kind Of Shareholders Hold The Majority In Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shares? - Yahoo Lifestyle UK

Yahoo Lifestyle UK

College of Pharmacy and Health Sciences Partners with Relmada Therapeutics, Inc. - St John's University News

St John's University News

Relmada Therapeutics Developing REL-1017 to Treat Major Depression - BioSpace

BioSpace

Relmada Therapeutics: A Promising Depression Focused Player For 2020 (NASDAQ:RLMD) - Seeking Alpha

Seeking Alpha

Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment ... - PR Newswire

PR Newswire

Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor ... - PR Newswire

PR Newswire